Vivos Therapeutics, Inc. (VVOS)
NASDAQ: VVOS · Real-Time Price · USD
4.120
-0.280 (-6.36%)
At close: Sep 5, 2025, 4:00 PM
4.210
+0.090 (2.18%)
After-hours: Sep 5, 2025, 7:40 PM EDT
Vivos Therapeutics Revenue
Vivos Therapeutics had revenue of $3.82M in the quarter ending June 30, 2025, a decrease of -5.77%. This brings the company's revenue in the last twelve months to $14.39M, up 2.65% year-over-year. In the year 2024, Vivos Therapeutics had annual revenue of $15.03M with 8.91% growth.
Revenue (ttm)
$14.39M
Revenue Growth
+2.65%
P/S Ratio
2.46
Revenue / Employee
$132,046
Employees
109
Market Cap
30.92M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 15.03M | 1.23M | 8.91% |
Dec 31, 2023 | 13.80M | -2.22M | -13.87% |
Dec 31, 2022 | 16.02M | -861.00K | -5.10% |
Dec 31, 2021 | 16.89M | 3.82M | 29.23% |
Dec 31, 2020 | 13.07M | 1.67M | 14.68% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
VVOS News
- 14 days ago - Vivos Therapeutics, Inc. (VVOS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 17 days ago - Vivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update - GlobeNewsWire
- 17 days ago - Vivos Therapeutics Schedules Release of Second Quarter 2025 Financial Results and Conference Call - GlobeNewsWire
- 2 months ago - New Clinical Trial Data Published Showing Positive Results from Use of Vivos Technology to Treat Obstructive Sleep Apnea in Children - GlobeNewsWire
- 4 months ago - Vivos Therapeutics, Inc. (VVOS) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Vivos Therapeutics Schedules Release of First Quarter 2025 Financial Results and Conference Call - GlobeNewsWire
- 5 months ago - Vivos Therapeutics Signs Definitive Agreement to Acquire Largest Sleep Center Operator in Nevada - GlobeNewsWire
- 5 months ago - Vivos Therapeutics, Inc. (VVOS) Q4 2024 Earnings Call Transcript - Seeking Alpha